563 related articles for article (PubMed ID: 28870198)
21. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
[TBL] [Abstract][Full Text] [Related]
22. Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype.
He Q; Jing H; Liaw L; Gower L; Vary C; Hua S; Yang X
Sci Rep; 2016 Mar; 6():23216. PubMed ID: 26976794
[TBL] [Abstract][Full Text] [Related]
23. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
24. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
25. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1.
Bao B; Azmi AS; Aboukameel A; Ahmad A; Bolling-Fischer A; Sethi S; Ali S; Li Y; Kong D; Banerjee S; Back J; Sarkar FH
J Biol Chem; 2014 May; 289(21):14520-33. PubMed ID: 24719318
[TBL] [Abstract][Full Text] [Related]
27. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
28. Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma.
Skoda J; Hermanova M; Loja T; Nemec P; Neradil J; Karasek P; Veselska R
PLoS One; 2016; 11(7):e0159255. PubMed ID: 27414409
[TBL] [Abstract][Full Text] [Related]
29. Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.
Chen JH; Kuo KT; Bamodu OA; Lin YC; Yang RB; Yeh CT; Chao TY
Exp Cell Res; 2018 Sep; 370(2):444-453. PubMed ID: 29981340
[TBL] [Abstract][Full Text] [Related]
30. Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines.
Kubo M; Umebayashi M; Kurata K; Mori H; Kai M; Onishi H; Katano M; Nakamura M; Morisaki T
Anticancer Res; 2018 Jul; 38(7):4273-4279. PubMed ID: 29970561
[TBL] [Abstract][Full Text] [Related]
31. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
32. Development and characterization of two human triple-negative breast cancer cell lines with highly tumorigenic and metastatic capabilities.
Su Y; Pogash TJ; Nguyen TD; Russo J
Cancer Med; 2016 Mar; 5(3):558-73. PubMed ID: 26775583
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of putative markers of cancer stem cells in gastric cancer: A retrospective cohort study.
Chen XL; Chen XZ; Wang YG; He D; Lu ZH; Liu K; Zhang WH; Wang W; Li CC; Xue L; Zhao LY; Yang K; Liu JP; Zhou ZG; Hu JK; Mo XM
Oncotarget; 2016 Sep; 7(38):62049-62069. PubMed ID: 27557490
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Sonic Hedgehog Signaling Pathway by Thiazole Antibiotic Thiostrepton Attenuates the CD44+/CD24-Stem-Like Population and Sphere-Forming Capacity in Triple-Negative Breast Cancer.
Yang N; Zhou TC; Lei XX; Wang C; Yan M; Wang ZF; Liu W; Wang J; Ming KH; Wang BC; Xu BL; Liu Q
Cell Physiol Biochem; 2016; 38(3):1157-70. PubMed ID: 26963129
[TBL] [Abstract][Full Text] [Related]
35. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
36. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
37. CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells.
Chen Y; Yu D; Zhang H; He H; Zhang C; Zhao W; Shao RG
Int J Biol Sci; 2012; 8(7):992-1004. PubMed ID: 22904667
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
39. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
[TBL] [Abstract][Full Text] [Related]
40. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
Navas T; Pfister TD; Colantonio S; Aziz A; Dieckman L; Saul RG; Kaczmarczyk J; Borgel S; Alcoser SY; Hollingshead MG; Lee YH; Bottaro DP; Hiltke T; Whiteley G; Takebe N; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
PLoS One; 2018; 13(6):e0199361. PubMed ID: 29928062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
